Seliciclib in malignancies

Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal Cancer

(2009) W.-S. Hsieh et al.   CLINICAL CANCER RESEARCH

Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatment

(2009) Józefa Węsierska-Gądek et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism

(2008) Gustavo Ortiz-Ferrón et al.   CELL RESEARCH

Synergistic Inhibition of ErbB Signaling by Combined Treatment with Seliciclib and ErbB-Targeting Agents

(2008) I. N. Fleming et al.   CLINICAL CANCER RESEARCH

Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicinin vivoin a breast cancer xenograft model

(2008) Maria Virginia C.L. Appleyard et al.   INTERNATIONAL JOURNAL OF CANCER

Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS3cervix carcinoma cells

(2008) Józefa Węsierska-Gądek et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases

(2008) K Bettayeb et al.   ONCOGENE